Formation

Forbion operates a joint venture with BioGeneration Ventures (BGV). Since their inception in 2006, BGV has managed over EUR 400 million across five funds.

BGV invests in partnerships with other professional investors in life sciences and has built strategic relationships with various academic institutions and leading healthcare companies as well as venture capital investors in the Netherlands, the EU and the US.

BGV has strategic partnerships with pharma companies as well as clinical and pre-clinical research and pharmaceutical manufacturing service companies. BGV and its portfolio companies benefit from direct access to broad know-how and capabilities of these partners as well as preferential terms for services

BioGeneration Ventures’ FIRST Fund (Fonds InvesteringsRijpe Starters) is a pre-seed fund that finances pioneering scientists in The Netherlands who are active in the emerging fields of regenerative medicine and cardiovascular diseases. 

FIRST supports leading scientists in these fields to transform their breakthrough discoveries into sustainable, innovative companies that can develop the products needed to improve patients' lives. We harness innovative science to foster its development into a product vision, and with our extensive network, attract follow-on investments.

FIRST is founded by the Dutch CardioVascular Alliance (DCVA) and Regenerative Medicine Crossing Borders (RegMed XB) with support of the Dutch Ministry of Economic Affairs and Climate Policy (under the TTT-regeling). The DCVA and RegMed XB are public-private partnerships that bring together the best scientists in The Netherlands to discover new regenerative and cardiovascular medicine and solutions to prevent and cure chronic diseases.